Nanobac Pharmaceuticals Inc. Announces Update for Shareholders and Interested Parties
Wednesday August 16, 9:52 am ET
TAMPA, Fla.--(BUSINESS WIRE)--Aug. 16, 2006--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News; "Nanobac" or "The Company") today provided the following updates:
The Company recently filed its 10Q for the quarter ending June 30, 2006. Company CEO John Stanton stated, "I want to take this opportunity to highlight a few matters and set the course for future actions and expectations.
"As you're probably aware from recent news releases by Nanobac, the Company has sharpened its focus now that its intellectual property is consolidated and we are beginning to receive more results from our research.
"Cover stories in major news media have made it clear that inflammation and calcification are among the most prevalent and unsolved disease conditions on the 'leading causes of death list.' Inflammation and calcification occur in heart disease, breast cancer, and stone-forming diseases such as kidney stones and prostatitis.
"More than 20,000 published medical papers refer to calcification. Until now no one has identified a definite cause of the deposits, so imagine the impact on medicine of being able to show a cause, as well as the capability to diagnose and treat pathological calcification effectively.
"What has excited us at Nanobac recently is the independent findings published by scientists at well-known institutions, supporting what our own scientists have maintained for years: that the type of calcification generated by nanobacteria (Calcifying Nanoparticles or CNPs as they are also known) is a cause of inflammation, and a contributor to the damaging deposits found in those diseases.
"That is precisely our focus at Nanobac, and here are the main areas of our revitalized R&D program:
Therapy. The Company is entering into agreements to test its proprietary drug combination against stone-forming diseases, with a preliminary focus on prostatitis, which affects millions of men and is largely untreatable today, along with other stone forming diseases such as gallstones and kidney stones. Contracts have been entered into and we expect the first part of the trial to begin in the third quarter of 2006.
Proving Infection. The gold standard for proving that something is infectious is "Koch's postulates." In June of 2006, a new study published by independent scientists in a peer reviewed journal demonstrated key elements of Koch's postulates by showing that CNPs are implicated in formation of black pigment gallstones in an animal model. Until now there was no known cause of such gallstones that affect millions of persons. Nanobac is now entering into an agreement to validate this finding with the same scientists. Work will begin immediately. We are very excited about this landmark finding.
Identifying Infection Mechanisms. The Company has preliminary photographic and biochemical evidence that calcifying nanoparticles self-replicate, suggesting that they have a self-sustaining mechanism and might be infectious. In a new agreement with the Fetzer Memorial Trust, Nanobac recently began an experiment at its own laboratories at NASA in Houston to demonstrate this replication via time-lapse photography, using new award-winning CytoViva microscope technology capable of breaking through the 200 nanometer (nm) barrier for light microscopes. Our Scientific Director at the Johnson Space Center has very recently obtained proof of concept that this can be done, by taking preliminary photographs of CNPs at never-before-seen magnifications for real-time photography. Nanobac owns all IP arising from this particular experiment.
Thrombosis is the cause of death in most hemodialysis patients. The Company intends to validate its findings that calcifying nanoparticles discovered in human blood provoke thrombosis and might be preventable.
Diagnostics. The Company believes it has identified precisely what its proprietary Elisa antibody test is uniquely recognizing on calcifying nanoparticles, and has begun validating this finding.
"You can expect more information on these initiatives in the near future and results by early 2007.
"We have fortified our findings with patents to protect our exclusive capacities for diagnosis and therapy. The objection period for our nanobacteria eradication patent has expired without objections being filed, thus providing another valuable tool to turn our scientific findings into profits for our shareholders."
About Nanobac Pharmaceuticals
Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.
Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: nanobac.com .
Contact:
Nanobac Pharmaceuticals Inc., Tampa
Douglas Mulhall, 813-262-9025
dmulhall@nanobaclabs.com
or
Redwood Consultants, LLC
415-884-0348
InvestorInfo@RedwoodConsultants.com
--------------------------------------------------------------------------------
Source: Nanobac Pharmaceuticals Inc. |
